HDAC9 and neoplasm: Inhibition of HDAC not only lead to the accumulation of activated p53, but also modified the hyperacetylation of p53 to enhance the anti-tumor activity of MDM2 inhibitors (Xu et al., 2007; McCormack et al., 2012).